Andrew Tsai
Stock Analyst at Jefferies
(0.35)
# 4,142
Out of 4,896 analysts
20
Total ratings
23.53%
Success rate
-32.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $54 | $18.17 | +197.19% | 2 | Jun 16, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $104.83 | +4.93% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $2.96 | -15.54% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $109.04 | +83.43% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.48 | +46.10% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.61 | +2,031.15% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $14.59 | +139.89% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.60 | +1,169.23% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.38 | +530.25% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $1.08 | +177.78% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.43 | +589.97% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.05 | +148.45% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.62 | +930.53% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $32.17 | -28.50% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jun 16, 2025
Maintains: Buy
Price Target: $125 → $54
Current: $18.17
Upside: +197.19%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $104.83
Upside: +4.93%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $2.96
Upside: -15.54%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $109.04
Upside: +83.43%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.48
Upside: +46.10%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.61
Upside: +2,031.15%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $14.59
Upside: +139.89%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.60
Upside: +1,169.23%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.38
Upside: +530.25%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.08
Upside: +177.78%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.43
Upside: +589.97%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $8.05
Upside: +148.45%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $2.62
Upside: +930.53%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $32.17
Upside: -28.50%